Latest News

Thursday, May 17, 2018

Growing Evidence for Cannabidiol to Treat Lennox Gastaut Syndrome and Dravet Syndrome

May 17, 2018 -- Results of a phase 3 clinical trial comparing adjunctive treatment with cannabidiol (CBD) (Epidiolex; GW Pharmaceuticals/Greenwich Biosciences, Carlsbad, CA) to placebo showed that add…

Read the full story

Wednesday, May 16, 2018

Potential New Rescue Therapy for Cluster Seizures, Midazolam Nasal Spray, Acquired by UCB

UCB has announced an agreement to acquire the rights to midazolam nasal spray (USL261), intended as a rescue therapy for acute repetitive series (ARS), or cluster seizures.  The company expects t…

Read the full story

Tuesday, May 15, 2018

Poor Blood-Pressure Control Related to More Lacunar Strokes at Earlier Age

While elevated blood pressure is a well-established risk factor for stroke, there has been debate regarding the roll of elevated blood pressure in lacunar stroke with some studies suggesting that hype…

Read the full story

Thursday, May 10, 2018

Retinal Deposits of Phosphorylated Alpha-Synuclein: A Biomarker for Parkinson’s Disease?

Analysis of retinas from 19 autopsied subjects, 9 with Parkinson’s disease (PD), and 4 with incidental Lewy body disease, showed accumulation of phosphorylated α‐synuclein (AS) that was …

Read the full story

Wednesday, May 09, 2018

FDA Issues Recommendation on Neurovascular Stents Used for Stent-Assisted Coiling of Unruptured Brain Aneurysm

The US Food and Drug Administration (FDA) has issued a letter to health care providers that gives recommendations on patient selection and use of neurovascular stents for stent-assisted coiling (SAC) …

Read the full story

Wednesday, May 09, 2018

Depression in Older Adults May Be Linked to Memory Loss

In a study published in the journal  Neurology, researchers Zeki Al Hazzour, Michelle R. Caunca, Juan Carlos Nobrega, and others showed that depression in older adults correlates to worse ba…

Read the full story

Tuesday, May 08, 2018

Amantadine-Extended Release: Different Pharmocokinetics Drive Different Clinical Effects

Amantadine-ER (Gocovri; Adamas, Emeryville, CA) is approved by the Food and Drug Administration (FDA) for treatment of dyskinesia in patients with Parkinson’s disease taking levodopa therapy wit…

Read the full story

Monday, May 07, 2018

Nonmotor Symptoms of Parkinson’s Disease Underreported and Undertreated

More than 2 in 3 patients with Parkinson’s disease (PD) or their caregivers affirm the presence of nonmotor symptoms that significantly and negatively affect their quality of life. Of 3,500 peop…

Read the full story

Friday, May 04, 2018

OnabotulinumtoxinA for Migraine Has Long-Term Safety and Efficacy

A wealth of results showing the long-term safety and efficacy of onabotulinumtoxinA (Botox; Allergan, Dublin, Ireland) for treating patients with migraine were presented at the recent American Academy…

Read the full story

Wednesday, May 02, 2018

Noninvasive, Cost-Effective Neuromodulation Therapy for Migraine and Cluster Headache

At the recent American Academy of Neurology meeting in Los Angeles, CA, electroCore, a commercial-stage bioelectronic medicine company, presented data from the PRESTO study of a hand-held noninvasive …

Read the full story

Tuesday, May 01, 2018

Premarket Approval for Deep Brain Stimulation for Treatment of Patients with Refractory Partial Onset Seizures

The Food and Drug Administration (FDA) has granted premarket approval of deep brain stimulation (DBS) therapy to Medtronic (Dublin, Ireland) for adjunctive treatment to reduce frequency of partial-ons…

Read the full story

Monday, April 30, 2018

Treating Patients With Essential Tremor with Wristwatch-Style Neuromodulation

Using a wrist-worn neuromodulation device (Cala Health Inc, Burlingame, CA) that stimulates the radial and median nerves, people with essential tremor may find some relief from a new, noninvasive type…

Read the full story

Friday, April 27, 2018

Perampanel Safety, Efficacy, and Predictors of Major Response

Perampanel (FYCOMPA; Eisai, Woodcliff Lake, NJ) is approved for use as monotherapy for treatment of partial-onset seizures (POS) with or without secondarily generalized seizures (SGS) and as adjunctiv…

Read the full story

Thursday, April 26, 2018

OnabotulinumtoxinA: Safety and Efficacy for Treating Children With Spasticity in Cerebral Palsy

At the American Academy of Neurology (AAN), researchers Heakyung Kim, Jill Meilahn, Chengcheng Liu, Henry G. Chambers, and Rozalina Dimitrova presented results evaluating the efficacy and safety of on…

Read the full story

Wednesday, April 25, 2018

Ocrelizumab Delays Cognitive Decline and Reduces Disease Activity and Disability Progression in Patients With MS

New data on ocrelizumab (OCREVUS; Genentech, South San Francisco, CA) were presented at the American Academy of Neurology this week, including results from 4 years of continuous treatment of patients …

Read the full story
Load More